letter Open AccessTop 1% cited
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
New England Journal of Medicine · 2016 · Vol. 375(19) · pp. 1834–1844
Steven P. Marso✉(Research Medical Center)Stephen C. Bain(Swansea University)Agostino Consoli(Swansea University)Freddy G. Eliaschewitz(Swansea University)Esteban Jódar(Universidad Europea de Madrid)Lawrence A. Leiter(St. Michael's Hospital)Ildiko Lingvay(Swansea University)Julio Rosenstock(Swansea University)Jochen Seufert(Swansea University)Mark Warren(Physicians East)Vincent Woo(University of Manitoba)Oluf H. Hansen(Swansea University)Anders G. Holst(Swansea University)Jonas Pettersson(Novo Nordisk (Finland))Tina Vilsbøll(University of Copenhagen)
Abstract
In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide. (Funded by Novo Nordisk; SUSTAIN-6 ClinicalTrials.gov number, NCT01720446 .).
Diabetes Treatment and ManagementMetabolism, Diabetes, and CancerDiabetes Management and ResearchSemaglutideType 2 diabetesMedicineDiabetes mellitusInternal medicineCardiologyEndocrinologyLiraglutide
MeSH terms
SemaglutideAgedCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesDiabetic RetinopathyGlucagon-Like PeptidesFemaleGastrointestinal DiseasesGlycated HemoglobinHumansMaleMiddle AgedGlucagon-Like Peptide 1Kaplan-Meier Estimate
Funding
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Intarcia Therapeutics
- MannKind Corporation
- Medicines Company
- Mylan
- Novo Nordisk
- Servier
Citations
6,314
FWCI
393.36
field-weighted impact
References
15
Percentile
100%
vs. same field & year
Citations per year
Cited by
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Hepatology · 2023 · 2,046 citations
2018 ESC/ESH Guidelines for the management of arterial hypertension
European Heart Journal · 2018 · 10,258 citations
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Kidney International · 2022 · 1,122 citations
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Circulation · 2019 · 4,494 citations
2018 ESC/ESH Guidelines for the management of arterial hypertension
Journal of Hypertension · 2018 · 2,790 citations
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Kidney International · 2020 · 1,379 citations
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
European Heart Journal · 2019 · 4,808 citations
References
Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus
Gut · 2012 · 6,830 citations
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
New England Journal of Medicine · 2015 · 11,756 citations
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Journal of Medicinal Chemistry · 2015 · 989 citations
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine · 2016 · 7,103 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.